The selectivity of such approaches in targeting specific cell populations, as it has been reported for tumor-promoting M2 macrophages [125], may suggest that the selective target of c-MYC holds promise for more effective and tailored cancer treatments through targeting pro-tumoral cancer cell/CAFs crosstalk. The gene discussed is MYC; the disease is neoplasm.